Stem Cell Therapy for liver cirrhosis and chronic liver disease in Turkey – Istanbul
- Written by
- StemCell Longevita Editorial Team
- Medically reviewed by
- Prof. Dr. Erdal Karaöz TeamProfessor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
- Last reviewed
- Next scheduled review
How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards
Clinical guide to MSC therapy for liver cirrhosis in Turkey: evidence, staging, transplant red flags, candidacy, exclusions and Istanbul medical planning.
Evidence at a glance — Chronic liver disease and cirrhosis
A plain summary of what the published research does and does not show for this condition. It is written to the same standard whether the evidence is strong or weak.
- Human studies available?
- Yes — including controlled studies
- Randomised trials?
- Randomised trials and meta-analyses exist, largely from single regions; results are heterogeneous
- Main outcomes studied
- MELD/Child-Pugh score
- Albumin and bilirubin
- Transplant-free survival
- Safety
- Long-term evidence
- Limited
- Regulatory approval for this indication
- United States (FDA): No FDA-approved mesenchymal stem cell product for this indication. The FDA has issued consumer warnings about unapproved stem cell products.
- European Union (EMA): No EMA-authorised mesenchymal stem cell medicine for this indication.
- United Kingdom (MHRA): No MHRA-authorised mesenchymal stem cell medicine for this indication.
- Türkiye (Ministry of Health): In Türkiye, cell therapies are delivered only inside Ministry of Health–licensed centres under the regenerative medicine / advanced therapy regulations, as clinical research or individual (exceptional) use — not as an approved routine treatment for this indication.
- Role at our centre
- Research context — considered only where standard care is exhausted or unsuitable, and never as a replacement for it
What kind of evidence exists
- Mechanism (laboratory): Documented
- Animal / preclinical: Documented
- Early human (phase 1/2, uncontrolled): Documented
- Controlled human (randomised or sham-controlled): Documented
- Regulatory approval: Not established
Sources
- Systematic reviews and meta-analyses — Chronic liver disease and cirrhosis — PubMed
- Randomised controlled trials — Chronic liver disease and cirrhosis — PubMed
- Registered MSC trials — Chronic liver disease and cirrhosis — ClinicalTrials.gov
- FDA — Consumer alert on regenerative medicine therapies — U.S. Food and Drug Administration, 2024
- Advanced therapy medicinal products: overview — European Medicines Agency, 2025
- ISSCR Guidelines for Stem Cell Research and Clinical Translation — International Society for Stem Cell Research, 2021
- ISSCR Patient Handbook on Stem Cell Therapies — International Society for Stem Cell Research, 2020
Source links open filtered searches of PubMed and ClinicalTrials.gov plus regulator and professional-society pages, so you can read the current evidence yourself rather than a selected extract.
This summary is general information about the evidence base, not medical advice and not a promise of benefit. Whether any treatment is appropriate for you can only be decided after a medical review of your records.
Records before recommendations
A proposed route is discussed only after diagnosis, investigations, current care and travel fitness have been reviewed.
No outcome guarantee
The evidence, uncertainty and reasons not to proceed are explained. Established care remains part of the decision.
Plan for continuity
Istanbul logistics, discharge documents and follow-up should connect with the clinician managing care at home.
A decision guide for patients comparing care
This page is for patients and families researching regenerative options for liver cirrhosis and chronic liver disease and comparing an Istanbul medical review with care available at home. It explains the evidence limits, questions that determine candidacy, reasons not to travel, protocol decisions, realistic expectations, costs and return-home follow-up.
Before considering stem cell therapy for liver cirrhosis and chronic liver disease
The key question: What is the cause and stage of liver disease, and is the patient stable enough for an elective investigational discussion rather than urgent specialist care?
Evidence status
MSC therapy for cirrhosis remains investigational. It cannot be assumed to reverse fibrosis or replace hepatology care, cause treatment or transplant assessment.
Standard care first
Hepatology management, alcohol or metabolic risk treatment, antiviral therapy when indicated, surveillance and transplant referral remain central.
What the review checks
Cause, Child–Pugh and MELD information, imaging, portal hypertension, ascites, encephalopathy, bleeding history, infection and transplant status.
When we redirect
Decompensation, active bleeding, encephalopathy, sepsis, suspected cancer or need for urgent transplant assessment requires local specialist care.
Planning treatment in Istanbul
Confirm travel fitness, medication and nutrition needs, companion support, emergency contingencies and direct communication with the home hepatology team.
How are stem cell and exosome approaches discussed for liver cirrhosis and chronic liver disease?
MSC research in chronic liver disease explores inflammatory signalling and support of the tissue environment. It does not establish that an infusion reverses cirrhosis, removes portal hypertension or replaces treatment of the underlying cause.
The first decision is whether disease is compensated and stable enough for elective review. Transplant red flags, cancer surveillance and urgent complications take priority over any regenerative discussion.
Who may be considered?
Candidacy is never decided from age or diagnosis alone. A medical review looks for a clear clinical question, stable health, appropriate prior care and goals that can be followed after return home.
- A known cause and stage of liver disease with recent laboratory and imaging results
- Compensated, clinically stable disease without urgent transplant red flags
- Ongoing hepatology care and a clear return-home monitoring plan
Who may not be suitable?
Decompensation, active bleeding, encephalopathy, sepsis, suspected cancer or need for urgent transplant assessment requires local specialist care.
Active infection, unstable medical disease, pregnancy, active cancer treatment or inability to complete safe follow-up also require postponement, redirection or further specialist review.
How is a protocol for liver cirrhosis and chronic liver disease planned?
Route, dose, session count and stay length cannot be responsibly prescribed from a webpage. The written plan follows record review and should explain why each element is being proposed.
- 1
Records and diagnosis review
Recent specialist reports, investigations, medication and previous treatment are reviewed to confirm the clinical question and whether liver cirrhosis and chronic liver disease is stable enough for elective travel.
- 2
Product and route discussion
If an investigational option is discussed, the team should identify the cell or exosome product, source, testing, proposed route and why that route is being considered. No fixed dose or route is appropriate for every patient.
- 3
Individual written plan
Session count, timing, monitoring and supportive care are documented only after medical review. The plan should explain uncertainty, alternatives and what would cause treatment to be postponed or declined.
- 4
Discharge and follow-up handover
Patients receive product and procedure documentation, medication instructions, warning signs and a follow-up plan that can be shared with their clinician at home.
What results can realistically be expected?
The purpose of follow-up is to measure safety and agreed clinical goals—not to retrofit ordinary variation into a success claim.
- There is no guaranteed response and no promise of cure, reversal, remission, tissue regrowth or stopping established medication.
- Any goals should be condition-specific and measurable—for example function, symptoms, participation or rehabilitation tolerance—rather than a broad claim of regeneration.
- The timing of any change is uncertain. Immediate post-procedure observations, later clinical review and longer-term follow-up serve different purposes; published research cannot predict an individual outcome.
- No change, temporary symptoms or the need for further local assessment are possible outcomes and should be discussed before travel.
Why patients consider StemCell Longevita for liver cirrhosis and chronic liver disease
Patients may choose StemCell Longevita when they want an Istanbul review pathway built around records, written decisions and return-home coordination rather than a promise of results. These are the service standards to confirm during consultation:
Records are reviewed before a treatment recommendation or travel booking is requested
The medical team can explain why an enquiry may be declined or redirected
The proposed product, source, testing, route and traceability documents are identified in writing
Investigational options are distinguished from established treatment and medication is not stopped without the home clinician
The quotation separates clinical services, travel support, exclusions and potential extra costs
Discharge documents and a follow-up pathway are prepared for continuity with the home specialist
International patient journey for liver cirrhosis and chronic liver disease
Confirm travel fitness, medication and nutrition needs, companion support, emergency contingencies and direct communication with the home hepatology team.
- 1
Private record review
Send recent reports, imaging or test results and a current medication list. The team may request more information or advise against travel.
- 2
Written planning before booking
Confirm the proposed intervention, evidence status, exclusions, estimated stay, companion or accessibility needs, package inclusions and total quoted cost.
- 3
Assessment in Istanbul
Clinical review on arrival confirms that health status and records still support the plan. Treatment should be paused if new risks are identified.
- 4
Discharge and return home
Travel timing and support are adapted to liver cirrhosis and chronic liver disease. Warning signs, medication continuity and relevant documents are reviewed before departure.
- 5
Remote follow-up
Scheduled check-ins document safety and agreed outcomes, while the home specialist remains responsible for established disease management and urgent care.
How much does treatment for liver cirrhosis and chronic liver disease cost in Turkey?
A responsible quotation follows medical review. It should show the proposed clinical service and travel support separately enough for you to compare it with options in the UK, US, Germany or another home country.
- Condition-page prices are not quoted before records are reviewed because product, route, session structure, monitoring and travel support can differ.
- Ask for one written total showing the clinical service, laboratory or product documentation, hospital fees, tests, medication, transfers, accommodation and follow-up—and what is not included.
- Comparisons with the UK, US, Germany or another home country should compare like-for-like private services, not imply that an investigational intervention is equivalent to licensed standard care.
Frequently asked questions about liver cirrhosis and chronic liver disease
Related clinical questions
Where this page sits in the wider picture.